No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 32.5x · 10Y median 36.8x · 30th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:53:05.783Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for RenovoRx, Inc. (RNXT) stock was $1.43 as of Oct 6, 2026, 1:50 PM EDT, down 3.06% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +11.3% · 3-year avg +8.5%/yr · 5-year avg -23.8%/yr
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies.
Biotechnology · Mountain View, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.05
Revenue Est.
$1.06M
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.07
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RNXT | $64.20M | $1.43 | -3.06% | +11.31% | -23.80% | N/A | N/A |
| 2HRTX | $63.84M | $0.34 | -8.84% | -71.80% | -48.61% | -31.88% | vs RNXT |
| 3INCR | $63.79M | $5.38 | -1.19% | -32.59% | -30.85% | N/A | vs RNXT |
| 4GOSS | $64.97M | $10.63 | -0.17% | -94.75% | -59.51% | N/A | vs RNXT |
| 5ALPS | $63.23M | $0.38 | -5.00% | N/A | N/A | N/A | vs RNXT |
| 6PLRX | $63.16M | $1.02 | -0.97% | -32.11% | -43.17% | N/A | vs RNXT |
N/A
$909000.00
vs Estimate
$703750.00
Consensus Rating
Based on 4 analysts
Average Price Target
$7.13
+400.0% upside
Low
$3.00
Current
$1.43
High
$14.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.08 | $-0.06 | $-0.04 | 2 |
| Quarter ending Dec 2026 | $-0.08 | $-0.06 | $-0.03 | 2 |
| Quarter ending Mar 2027 | $-0.06 | $-0.06 | $-0.05 | 1 |
| Quarter ending Jun 2027 | $-0.05 | $-0.04 | $-0.04 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.30 | $-0.26 | $-0.23 | 2 |
| FY 2027 | $-0.23 | $-0.14 | $-0.05 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.01M | $1.06M | $1.12M | 3 |
| Quarter ending Dec 2026 | $1.23M | $1.34M | $1.44M | 3 |
| Quarter ending Mar 2027 | $1.40M | $1.54M | $1.66M | 1 |
| Quarter ending Jun 2027 | $2.21M | $2.43M | $2.62M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.71M | $3.88M | $4.04M | 3 |
| FY 2027 | $10.61M | $11.51M | $12.41M | 3 |
